Anti-Obesity Drug Discovery and Development

Anti-Obesity Drug Discovery and Development

Volume: 3

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



The Role of Gut Microflora in Obesity - Does the Data Provide an Option for Intervention?

Pp. 204-227 (24)

Parth J. Parekh, Edward C. Oldfield, Amrit Lamba and David A. Johnson

Abstract

The obesity epidemic has proven to have a significant burden on the current of state of healthcare. At an individual level, obesity and its sequelae have numerous effects on the state of health and quality of life. On a global perspective, treatment of obesity and its sequelae come at a high cost. Obesity, in terms of intestinal dysbiosis, is a complicated disequilibrium that offers many unclear complications. Thus, restoration of the commensal microflora serves a potential therapeutic option in combatting the obesity epidemic be it via antibiotic therapy, probiotics, prebiotics, symbiotics (combination of prebiotic and probiotic therapy), or fecal microbiota transplant. This manuscript will review the role of intestinal dysbiosis in the pathogenesis of obesity and the potential role for microflora manipulation as therapy.

Keywords:

Antibiotics, Butyrate, Dysbiosis, Fecal Microbiota Transplant, FFAR, Fiaf, Metabolic Endotoxemia, Microbiota, Obesity, Prebiotics, Probiotics, Proprionate, SCFAs, Symbiotics.

Affiliation:

Division of Gastroenterology and Hepatology, Eastern Virginia Medical School, Norfolk, VA 23510, USA.